Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. - Test2 - elhamkhani - TriplyDB

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

http://www.wikidata.org/entity/Q33382552

about

Liver transplantation: Current status and challenges The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients Current state of renal transplant immunosuppression: Present and future Late and chronic antibody-mediated rejection: main barrier to long term graft survival Modern approaches to incompatible kidney transplantation The importance of C4d in biopsies of kidney transplant recipients Treatment options and strategies for antibody mediated rejection after renal transplantation The divergent roles of macrophages in solid organ transplantation Unraveling the Role of Allo-Antibodies and Transplant Injury The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report.Bortezomib use in a pediatric cardiac transplant center.Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment.Use of bortezomib as anti-humoral therapy in kidney transplantation.Current status of xenotransplantation and prospects for clinical application The effect of stem cell transplantation on immunosuppression in living donor renal transplantation: a clinical trial B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.Bortezomib in kidney transplantation.Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus Diagnosis and management of antibody-mediated rejection: current status and novel approaches.Bortezomib for acute antibody-mediated rejection in liver transplantation.Recent advances in renal transplantation: antibody-mediated rejection takes center stage Antibody-mediated rejection: an evolving entity in heart transplantation.Antibody-mediated rejection in kidney transplantation: a review Rational clinical trial design for antibody mediated renal allograft injury.Adult Living Donor Liver Transplantation Across ABO-Incompatibility.Plasma cell-rich acute rejection of the renal allograft: A distinctive morphologic form of acute rejection?Pathological diagnosis of antibody-mediated rejection in renal allograft without c4d staining, how much reliable?Human leukocyte antigen antibody incompatible renal transplantation Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients Successful Salvage Treatment of Resistant Acute Antibody-Mediated Kidney Transplant Rejection with Eculizumab.Report from a consensus conference on antibody-mediated rejection in heart transplantation Increased levels of anti-non-Gal IgG following pig-to-baboon bone marrow transplantation correlate with failure of engraftment Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.New immunosuppressive agents in pediatric transplantation.Impact of donor-specific antibodies on the outcomes of kidney graft: Pathophysiology, clinical, therapy.Advances in diagnosing and managing antibody-mediated rejection.

P2860

Q26749457-DBBCA75E-ACF5-4D99-AA6C-675786310EBD Q26774993-CDE559EA-2A15-4BE0-B19C-283697A5E925 Q26829789-A09AEDF9-610F-4C40-B844-0A00DDB20183 Q27006030-C5AA7AA8-7422-486F-971F-63712F741B34 Q27010224-2E323F6A-238B-492E-B372-A834A481AF90 Q27021227-71D34EBF-3266-429C-B552-F396C5A877F8 Q27021397-25E9ABF9-A8C1-4898-BFA4-8B18F72627B0 Q27022711-86739DF6-44C5-47E9-A2E6-A9829807396A Q28069336-D23D00C5-2EEB-48DA-BAB6-2D319E0C8704 Q30248842-924AC2B3-93D6-4A9D-BD69-FD405355501B Q33389918-DEC783E2-E1F9-4CBC-A824-974C614058B1 Q33414120-611F53CD-5809-4D63-9A02-24D608209561 Q33415926-21038BE4-6A86-463D-B5B7-8AE922A2931F Q33416169-F27CE95A-7E76-4D1A-A56D-065C06EDD42D Q33627580-648BB631-4809-4AE9-844C-606F14EF20F7 Q33835678-DA1C39DB-B51F-45ED-BF53-5B9DF111CC6E Q33872046-A80AF525-873F-47F5-B167-BD9E6082EE8A Q34159016-1EF3C76D-B4C0-4DEA-A8A7-D9D01368D4C1 Q34189435-073C6086-B002-4F7D-90C5-3F5A5F516858 Q34222399-69555C1F-CDF0-45A6-9398-93E6AA966E7D Q34464260-01AA8D37-B39A-49E4-842D-0C0B8F1D4E03 Q34841849-07606FB2-93F1-431B-90CA-712AC2A9563B Q35538969-FF258B07-BF40-47D5-8B3F-AA59450E6B8F Q35659332-5F01AE18-D9E3-4FB2-95C8-5F360AD1D995 Q35876250-6FC4F25F-0A04-4BE0-8F4F-2AE7D8A289D3 Q35915453-E17451CB-8270-41E2-8A06-F04B279FFE76 Q36173541-F2D3963A-CCCF-47C3-B6F2-4E47F62188C7 Q36206934-BB8C40E6-4EA5-4B22-8DCC-48C2D784637E Q36283539-88A5BBB7-2BB9-40A5-BB54-7B6C74198F41 Q36529421-6CB41993-4A74-4B12-8049-852BE761282F Q36612789-AF9AC039-F4D7-4FB5-B667-5293A8441E8E Q36752176-767D80ED-5A88-42F9-A22D-1C82A6DAED31 Q37013494-18B02FFC-6991-4AC8-9165-BE563A3599DD Q37200645-87D14A19-04EA-4B9F-A8B9-32D002D0F0FF Q37313051-746DE0B9-5377-44CB-BCF4-7EB7FF76719A Q37358501-DC9EEA0E-3494-48F1-A599-1DDC941418EF Q37361071-9C34866E-8BF9-4C63-A345-EEED2F63DA27 Q37446883-179B10C4-1C24-47A7-A622-B1604E4DF24E Q37660263-4DC48AA2-1232-44F1-BD24-97B54348296A Q37676032-2714EF3C-E32B-4855-AD59-3DDF0E196397

P2860

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

http://www.wikidata.org/entity/Q33382552

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@ast

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@en

type

label

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@ast

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@en

prefLabel

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@ast

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@en

P1433

Q33382552-FC25DD17-CD99-4AF8-BF16-5C8D7DD748D8

P1476

Q33382552-6EFF5AB2-5AD4-4C29-841D-044B5FE663FF

P2093

Q33382552-01FDAB3D-27FB-4F32-BE8B-ED951AF38D0C

Q33382552-0DD047B5-D421-4E71-8FCC-FCDDE61572DB

Q33382552-27D2D973-9CA6-410A-AE1D-6563CB18F1ED

Q33382552-584E835F-CCE3-4EB3-9E2A-0C7447E9FA24

Q33382552-5ADD42EE-B272-46F2-8CC1-7641A39BF010

Q33382552-6190DDBC-3E83-48EF-A6A6-5BE56CADCE97

Q33382552-6E3A9252-E461-4BCC-A931-67626B2929C4

Q33382552-948C3F57-D5A0-4312-BBE6-F82C364EE65B

Q33382552-AD9ED7FB-2A13-4C93-8678-824FEDFFED68

Q33382552-BFD17B47-A60B-4946-8347-74A95C61C3EC

P304

Q33382552-27BE6E44-C2EC-468A-9AA8-358C02B51E1C

P31

Q33382552-D1FFBF11-DEA4-4595-959B-3C86DC7157D4

P356

Q33382552-E6C414D0-C76C-444D-AD12-C9721EFA6876

P433

Q33382552-32E4E80F-CEFA-4DF3-AF47-B95DD4C933DE

P478

Q33382552-12FBB1C4-A9F5-47DD-B1B2-EFEE8A99C3C6

P577

Q33382552-965C605C-CAFF-44E2-81F7-DFC6D22EFBFB

P698

Q33382552-996B0B20-A34A-4FCA-A117-2D4BD4DD7178

P921

Q33382552-ED27080E-C6C4-4171-98CA-C1CB1497D308

P356

TP.0B013E318190AF83

P1433

Transplantation

P1476

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

@en

P2093

Adele H Rike

http://www.w3.org/2001/XMLSchema#string

Amit Govil

http://www.w3.org/2001/XMLSchema#string

Amit Tevar

http://www.w3.org/2001/XMLSchema#string

Brian Susskind

http://www.w3.org/2001/XMLSchema#string

E Steve Woodle

http://www.w3.org/2001/XMLSchema#string

Gautham Mogilishetty

http://www.w3.org/2001/XMLSchema#string

George Wadih

http://www.w3.org/2001/XMLSchema#string

Jason J Everly

http://www.w3.org/2001/XMLSchema#string

Lois J Arend

http://www.w3.org/2001/XMLSchema#string

Matthew J Everly

http://www.w3.org/2001/XMLSchema#string

P304

1754-1761

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/TP.0B013E318190AF83

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19104417

http://www.w3.org/2001/XMLSchema#string

P921